When a patient goes in for elective plastic surgery, it
is most often with the thought that they are improving something
about their appearance. The physician keeps aesthetics and
symmetry in mind as the work is planned and done much as
a sculptor takes care to carve his artwork.
In serious injury when a fracture is compounded and sections
of broken bone tears through the skin, great care must be
taken not only in reducing the fracture but also in making
sure no nerve damage has been done by the break or created
in the reduction. The ends of bone are carefully placed back
where they can mend and the skin closed and sutured to insure
that it all heals. Ofttimes in car accidents facial lacerations occur from
flying shards of glass. If the ER doctor is skilled at closing
such wounds he will first suture the gallia, the fine connective
tissue layer beneath the skin, mating the ends correctly
then carefully closing the skin over that. What happens after the events described above or any other
injury or surgical wound where skin and the connective tissue
layers beneath are involved hopefully is healing without
scaring and without the formations of keloids. What are keloids?
They are hard often unsightly mounds of connective tissue
bunched up and over grown; they are a form of fibrosis /
scar tissue. Fibrosis is the result of inflammation. Inflammation caused
by the injury, by the surgery, by a burn, whatever the cause
inflammation is one of two things that drive the growth of
fibrosis. (The other cause of fibrosis growth is estrogen
but that is not an operational factor in keloid formation.
Long term or intense inflammation is the spark that causes
the formation of these mounds of scar tissue). If the inflammation
can be brought under control the keloid formation might be
arrested. Plastic surgeons routinely have administered local
injections of cortisone in attempts to slow down the inflammation
and stop the formation of keloids. These attempts are mostly
failures and if pronounced the keloid itself may have to
be surgically excised, which may in turn begin the round
of keloid formation all over again. It has been taught that a keloid older than a year will
remain untreatable regardless of what is done short of surgery.
This line of thinking does not hold world wide. Physicians
in Central Europe and Japan have for decades been treating
various types of fibrosis, from post operative scar tissue,
to renal fibrosis, to pulmonary fibrosis with blends of orally
administered proteolytic enzymes specifically formulated
to be absorbed and act systemically. (1,2,3,4,5.6). To date
there are over 200 peer reviewed studies verifying both the
absorption and therapeutic action of such enzymes. (See www.enzymescience.com
in the abstracts archive). In Germany the use of systemic enzymes is standard in the
post operative prevention of scar tissue, where the enzymes
also decrease inflammation (without the side reactions or
toxicity of the NSAID’s or steroids), and speed the
healing of tissue. It was surmised by some surgeons that
if the enzymes could prevent the formation of post operative
scar tissue and existing fibrosis in other conditions, that
they could also lyse away the fibrosis of keloids. Their
assumption was correct.
While
no formal studies have yet been done on keloids specifically,
the lysing action of the enzymes on other types of fibrosis
has been studied and noted. Various plastic surgeons have
reported the removal of long standing keloids from their
patients. One interesting observation on the fibrosis lysing
effect of systemic enzymes came from a plastic surgeon
from California. This physician, while using a
multi-enzyme product to reduce both the inflammation
and post operative scar tissue in his patients, was taking
the product himself to lower visceral inflammation levels
and bring down CRP and Homocystine levels. After several
weeks on the product he reported that a 40 year old keloid
the size of a small egg that had grown on his left hand,
as the result of a compound fracture, had been completely
lysed away! Various other plastic surgeons report the removal
of long standing keloids from patients.
Up to now there has been no sure treatment
for the prevention or elimination of keloids. With the
use of Systemic Enzymes, there is now a powerful, effective,
yet completely safe and non toxic tool for the treatment
of this form of fibrosis. The effect
of enzymes is dose dependent and results may be seen
seen in weeks or some months depending on the size of
and circulation to the keloid.
1) Transport of Proteolytic Enzymes Across Caco-2 Cell Monolayers Bock
U.,1 Kolac C.,1 Borchard G.,1 KochK.,1 Fuchs
R.,1 Streichhan P.,2 and Lehr C.-M.1 1
Department of Biopharmaceutics and Pharmaceutical Technology,
University of Saarland, Saarbrücken, Germany 2 Mucos Pharma GmbH, Geretsried, Germany Pharmaceutical Research 1998, Vol. 15, No. 9, pp.
1393-1400. 2) Intestinal absorption of serrapeptase (TSP) in rats. Moriya N, Nakata M, Nakamura M, Takaoka M, Iwasa S, Kato
K, Kakinuma A. Biotechnol Appl Biochem. 1994 Aug;20 ( Pt 1):101-8. Biotechnology Research Laboratories, Takeda Chemical Industries
Ltd., Osaka, Japan. 3) Evaluation of Serratia peptidase in acute or chronic
inflammation of otorhinolaryngology pathology: a multicentre,
double-blind, randomized trial versus placebo. Mazzone A, Catalani M, Costanzo M, Drusian A, Mandoli A,
Russo S, Guarini E, Vesperini G. J Int Med Res. 1990 Sep-Oct;18(5):379-88. Institute of Clinical Otorhinolaryngology, University of
Naples, Italy. 4)
Anti-inflammatory and analgesic activity of ExCLzyme-EN® S.L.Bodhankar, A.U.Burhan, V.M.Kale, S.Banerjee and S. Risbud Bharati Vidyapeeth Deemed University, Poona College of Pharmacy,
Pune 411 038. Raj Biotech Pvt. Ltd., Pune 411038 Group Companies of Specialty Enzymes and Biochemicals Co.,
Chino, California 91710 and Advanced Biochemicals Ltd. Thane
400601. 5) Renal fibrosis: Role of impaired protein degradation
and potential therapeutic strategies Heidland A.1, Sebekova K.2, Paczek L.3, Teschner M.1, Daemmrich
J.4, Gaciong Z.3 1 Medical Faculty, University of Wuerzburg, 2 Institute
of Preventive and Clinical Medicine, Bratislava (Slovakia),
3 The Transplantation Institute Warsaw (Poland), 4 Institute
of Pathology, University of Wuerzburg (Germany) Kidney International 1997, Vol. 52, Suppl. 62, pp.
S 32- S 35 6) Enzymolysis of glomerular immune deposits in vivo with
dextranase/protease ameliorates proteinuria, hematuria, and
mesangial proliferation in murine experimental IgA nephropathy Gesualdo L., Ricanati S., Hassan M.O., Emancipator S.N.,
Lamm M.E. Institute of Pathology and the *Department of Pathology,
Veterans Administration Hospital, Case Western Reserve University,
Cleveland, Ohio 44106 J. Clin. Invest. 1990: Vol. 86, September 1990, pp. 715-722 |
